Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Malignant gliomas in adults.
Approximately 5% of patients with malignant gliomas have a family history of gliomas. Some of these familial cases are associated with rare genetic syndromes, such as neurofibromatosis types 1 and 2,… Expand
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
- H. Friedman, M. Prados, +11 authors T. Cloughesy
- Medicine
- Journal of clinical oncology : official journal…
- 1 October 2009
PURPOSE
We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.
… Expand
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
- P. Wen, D. Macdonald, +16 authors S. Chang
- Medicine
- Journal of clinical oncology : official journal…
- 10 April 2010
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance… Expand
Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma
- E. V. Van Meir, C. Hadjipanayis, A. Norden, H. Shu, P. Wen, J. Olson
- Medicine
- CA: a cancer journal for clinicians
- 1 May 2010
Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for patients with glioblastoma, the most aggressive glioma, although individually variable, has improved from an… Expand
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
- P. Richardson, H. Briemberg, +17 authors A. Amato
- Medicine
- Journal of clinical oncology : official journal…
- 1 July 2006
PURPOSE
To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma.
PATIENTS AND METHODS
Peripheral neuropathy… Expand
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
- A. Patnaik, L. Rosen, +21 authors G. Shapiro
- Medicine
- Cancer discovery
- 23 May 2016
UNLABELLED
We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 and… Expand
Bevacizumab for recurrent malignant gliomas
Background: Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, may have activity in recurrent malignant gliomas. At recurrence some patients appear to develop… Expand
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors
- M. Glantz, B. Cole, +5 authors J. Cairncross
- Medicine
- Neurology
- 23 May 2000
The Quality Standards Subcommittee seeks to develop scientifically sound, clinically relevant practice parameters for the practice of neurology. Practice parameters are strategies for patient… Expand
Management of brain metastases.
- P. Wen, J. Loeffler
- Medicine
- Oncology
- 1 July 1999
Brain metastases are the most common type of brain tumor in adults and are an increasingly important cause of morbidity and mortality in cancer patients. In recent years, important advances have been… Expand
Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases.
- E. Alexander, T. Moriarty, +5 authors J. Loeffler
- Medicine
- Journal of the National Cancer Institute
- 4 January 1995
BACKGROUND
The spread of systemic cancer to the brain is a common complication for cancer patients. Conventional radiotherapy offers modest palliation, and surgery is helpful only for the patient… Expand